Mild to moderate preoperative patellar tendinopathy may not significantly affect postoperative outcomes of ACL ...

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences grows sales to CHF 75.6 million for 2024 Financial Highlights Direct MagnetOs sales increased by 136% to ...

2014.11.004 6 Pernaa K, Koski I, Mattila K, Gullichsen E, Heikkil J, Aho AJ, Lindfors NC. Bioactive Glass S53P4 and Autograft Bone in Treatment of Depressed Tibial Plateau Fractures - A Prospective ...

Ad-hoc announcement pursuant to Article 53 of the SIX listing rulesKuros Biosciences grows sales to CHF 75.6 million for 2024Financial ...

Scientists resolved the mystery, showing the drug 'hijacks' a normal ... Feb. 25, 2025 — A bone marrow transplant process is safe and curative for adults with sickle cell disease, according to ...

2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the full year 2024 ...

Arthroscopic evaluations further confirmed solid integration of costal cartilage into the underlying subchondral bone with a smooth surface over the repair site. Conclusion: Free ACCT is a feasible ...

Weintraub Center for Reconstructive Biotechnology, Section of Prosthodontics, School of Dentistry, University of California, Los Angeles, California 90095, United States ...